Twice-daily radiation linked to better quality of life in lung cancer trial

Previously, the superior endpoint results of the NRG-LU005 (NCT03811002) survey assessing the summation of the immunotherapy cause atezolizumab (Tecentriq) to standard-of-care concurrent chemoradiation for limited-stage small-cell lung crab were reported astatine the American Society for Radiation Oncology 2024 Annual Meeting. Those results showed that adding atezolizumab did not amended wide endurance (OS) for this diligent population.